Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RARE study of repeated rhenium-188-HEDP versus radium-223 chloride in metastatic castration-resistant prostate cancer
NL-OMON48796Phase 3Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- May 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing Rhenium-188-HEDP with Radium-223 chloride (2 arms). Primary endpoint: Overall survival. Started May 2018; status: active, not recruiting.
02
Drugs
Rhenium-188-HEDPradium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON48796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48796.